# Circulating levels of MOTS-c in patients with breast cancer treated with metformin.

> PubMed lists PMID 36490309 in Aging as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36490309-mots-c:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36490309-mots-c/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-36490309-mots-c-v1.json
- Content SHA-256: `0549d6cfee560b3f854269c1919e69069c7534704e29f40fdf38d299d4cc2a6e`

## Claims and source pins

### Headline

Circulating levels of MOTS-c in patients with breast cancer treated with metformin. ([`pubmed-observation-pmid-36490309-2026-01-27-957110a704a5`](#source-pubmed-observation-pmid-36490309-2026-01-27-957110a704a5))

### Summary

PubMed lists PMID 36490309 in Aging as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36490309-2026-01-27-957110a704a5`](#source-pubmed-observation-pmid-36490309-2026-01-27-957110a704a5))

### Paragraph 1

PubMed lists PMID 36490309 in Aging as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36490309-2026-01-27-957110a704a5`](#source-pubmed-observation-pmid-36490309-2026-01-27-957110a704a5))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36490309-2026-01-27-957110a704a5`](#source-pubmed-observation-pmid-36490309-2026-01-27-957110a704a5))

## Sources

<a id="source-pubmed-observation-pmid-36490309-2026-01-27-957110a704a5"></a>
- **Circulating levels of MOTS-c in patients with breast cancer treated with metformin. · retained source version 1:2026-01-27:current:957110a704a564c1275e53531614c9d2b86c7e6c966efa2612b4155e9a3eb338** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36490309/) (`pubmed-observation-pmid-36490309-2026-01-27-957110a704a5`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Circulating levels of MOTS-c in patients with breast cancer treated with metformin." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-36490309-mots-c-v1.json SHA-256: 0549d6cfee560b3f854269c1919e69069c7534704e29f40fdf38d299d4cc2a6e.